Several investment firms raised their price targets for Revolution Medicines on November 6, 2026, a day after the company reported third-quarter results. One analyst raised the target to $350.00 per share.
RASONQUE generated $197.6 million in revenue during its first five weeks on the market. The FDA approved the cancer drug in late August. Its launch revenue far exceeded consensus estimates of about $25 million. More than 5,000 patients received treatment during the launch.
The company also reported a quarterly loss that was narrower than expected.